Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). 2001

S Garg, and R A Anderson, and C J Chany, and D P Waller, and X H Diao, and K Vermani, and L J Zaneveld
Section of Ob/Gyn Research, Rush University, Rush Presbyterian St. Luke's Medical Center, Chicago, IL, USA.

Vaginal prophylactic methodology may prevent heterosexual transmission of the HIV and other sexually transmitted disease-causing organisms as well as unplanned pregnancies. A new delivery system (ACIDFORM) was designed with acid-buffering, bioadhesive, and viscosity-retaining properties to (1) maintain the acidic vaginal milieu (the low pH inactivates many pathogens and spermatozoa), (2) form a protective layer over the vaginal/cervical epithelium (minimizing contact with pathogenic organisms), and (3) provide long-term vaginal retention. A Phase I clinical study with ACIDFORM provided initial information about its safety and showed the formation of a layer over the vaginal/cervical epithelium [1; Amaral et al., Contraception 1999;60:361-6]. To study the properties of the gel (without active ingredient) in more detail, ACIDFORM's acid-buffering, bioadhesive, viscosity-retaining, and spermicidal properties were compared in vitro to marketed formulations, and its long-term stability was assessed. ACIDFORM, either when titrated with NaOH or when mixed directly with semen, is highly acid buffering and much more effective than Aci-Jel, a commercial acid-buffering vaginal product. ACIDFORM adheres well to two model membranes (excised sheep vagina and cellophane) and is more bioadhesive than Conceptrol, Advantage S, Replens, Aci-Jel, and K-Y jelly. On dilution, ACIDFORM also retains its viscosity better than these marketed products. ACIDFORM is spermicidal and is stable for at least 2 years. These results suggest that ACIDFORM has advantages over presently marketed vaginal delivery systems. The gel may either be useful by itself as an antimicrobial contraceptive product or as a formulation vehicle for an active ingredient with antimicrobial and/or contraceptive properties.

UI MeSH Term Description Entries
D008297 Male Males
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000180 Acrylic Resins Polymers of high molecular weight which are derived from acrylic acid, methacrylic acid or other related compounds and are capable of being molded and then hardened to form useful components. Acrylic Resin,Resin, Acrylic,Resins, Acrylic
D012749 Sexually Transmitted Diseases Diseases due to or propagated by sexual contact. Venereal Diseases,STDs,STIs,Sexually Transmitted Infections,Disease, Sexually Transmitted,Disease, Venereal,Diseases, Sexually Transmitted,Diseases, Venereal,Infection, Sexually Transmitted,Infections, Sexually Transmitted,STI,Sexually Transmitted Disease,Sexually Transmitted Infection,Transmitted Infection, Sexually,Transmitted Infections, Sexually,Venereal Disease
D013089 Spermatocidal Agents Chemical substances that are destructive to spermatozoa used as topically administered vaginal contraceptives. Spermicidal Agents,Contraceptive Agents, Spermatocidal,Spermatocidal Drugs,Spermatocides,Spermicidal Contraceptive Agents,Vaginal Spermicides,Agents, Spermatocidal,Agents, Spermatocidal Contraceptive,Agents, Spermicidal,Agents, Spermicidal Contraceptive,Contraceptive Agents, Spermicidal,Drugs, Spermatocidal,Spermatocidal Contraceptive Agents,Spermicides, Vaginal
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

S Garg, and R A Anderson, and C J Chany, and D P Waller, and X H Diao, and K Vermani, and L J Zaneveld
December 1999, Contraception,
S Garg, and R A Anderson, and C J Chany, and D P Waller, and X H Diao, and K Vermani, and L J Zaneveld
May 2006, Contraception,
S Garg, and R A Anderson, and C J Chany, and D P Waller, and X H Diao, and K Vermani, and L J Zaneveld
December 2007, AAPS PharmSciTech,
S Garg, and R A Anderson, and C J Chany, and D P Waller, and X H Diao, and K Vermani, and L J Zaneveld
December 2008, Acta pharmaceutica (Zagreb, Croatia),
S Garg, and R A Anderson, and C J Chany, and D P Waller, and X H Diao, and K Vermani, and L J Zaneveld
February 2006, British journal of clinical pharmacology,
S Garg, and R A Anderson, and C J Chany, and D P Waller, and X H Diao, and K Vermani, and L J Zaneveld
September 2018, Expert opinion on drug safety,
S Garg, and R A Anderson, and C J Chany, and D P Waller, and X H Diao, and K Vermani, and L J Zaneveld
October 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
S Garg, and R A Anderson, and C J Chany, and D P Waller, and X H Diao, and K Vermani, and L J Zaneveld
December 2004, Contraception,
S Garg, and R A Anderson, and C J Chany, and D P Waller, and X H Diao, and K Vermani, and L J Zaneveld
August 2014, AAPS PharmSciTech,
S Garg, and R A Anderson, and C J Chany, and D P Waller, and X H Diao, and K Vermani, and L J Zaneveld
April 2011, Journal of young pharmacists : JYP,
Copied contents to your clipboard!